铂耐药卵巢癌的治疗进展

Progress in the treatment of platinum-resistant ovarian cancer

在妇科三大恶性肿瘤中,卵巢癌(OC)的致死率居于首位。手术联合化疗是OC的主要治疗方式,但约有70%的患者治疗后病情会复发,最终发生耐药,而这对于患者的后续治疗来说尤为关键,关乎着患者的生存期及生活质量。本文主要总结了铂耐药卵巢癌(CROC)的治疗进展。

Among the three major gynecological malignancies,ovarian cancer(OC)has the highest mortality rate.Surgery combined with chemotherapy is the main treatment method for OC,but about 70%of patients will relapse after treatment and eventually develop drug resistance,which is particularly critical for the follow-up treatment of patients,and is related to the survival period and quality of life of patients.This article summarizes the progress in the t reatment of platinum-resistant ovarian cancer(CROC).